US Patent

US8697125 — Tablet preparation without causing a tableting trouble

Formulation · Assigned to Takeda Pharmaceutical Co Ltd · Expires 2029-06-16 · 3y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a tablet preparation that is superior in formability and dissolution of a pharmaceutically active ingredient.

USPTO Abstract

The present invention provides a tablet without causing a tableting trouble, which is superior in the tablet formability, dissolution property of pharmaceutically active ingredient, and the like.

Drugs covered by this patent

alogliptin-benzoate (ALOGLIPTIN BENZOATE)

Patent Metadata

Patent number: US8697125
Jurisdiction: US
Classification: Formulation
Expires: 2029-06-16
Drug substance claim: No
Drug product claim: Yes
Assignee: Takeda Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.